Compare NTWK & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | BCTX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 28.8M |
| IPO Year | 1998 | N/A |
| Metric | NTWK | BCTX |
|---|---|---|
| Price | $3.28 | $4.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 27.4K | ★ 875.9K |
| Earning Date | 02-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $66,501,654.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | $77.39 | ★ N/A |
| Revenue Growth | ★ 7.70 | N/A |
| 52 Week Low | $2.14 | $4.10 |
| 52 Week High | $5.75 | $98.20 |
| Indicator | NTWK | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 41.08 |
| Support Level | $3.02 | $4.10 |
| Resistance Level | $3.17 | $4.56 |
| Average True Range (ATR) | 0.15 | 0.62 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 55.43 | 10.69 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.